BioRestorative Therapies(BRTX)

Focus: BioRestorative Therapies is a public biotechnology company focused on autologous stem cell therapy for degenerative diseases, currently in early-stage clinical development with minimal revenue generation.

Cell Therapy Gene Therapy

Profile data last refreshed 39m ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About BioRestorative Therapies

AI assessmentNot Hiring

No open roles listed right now. Follow BioRestorative Therapies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$401K

Pipeline & Clinical Trials

BRTX-100

Lumbar Disc Disease

PHASE_2

Clinical Trials (1)

NCT04042844A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Phase 2

Help build intelligence for BioRestorative Therapies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity in autologous stem cell therapy, a potentially transformative modality with significant commercial upside if BRTX-100 succeeds
Public company status provides liquidity and potential equity upside compared to private biotech peers
Early-stage pipeline allows hands-on involvement in clinical development and regulatory strategy from Phase 2 onwards

Watch Out For

Severe cash position ($548K as of FY 2025) with annual burn exceeding $8M creates existential financing risk and limited job security
Single clinical program in Phase 2 with only 1 active trial means minimal pipeline diversity and narrow margin for failure
Trivial revenue ($401K in FY 2025) and only 1 open position signal a company in survival mode rather than growth trajectory

Generated by Claude from BioRestorative Therapies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.